Spitalul Clinic Judetean de Urgenta Arad
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Spitalul Clinic Judetean de Urgenta Arad, the clinical research portfolio focuses on cardiovascular diseases and closely related neurology-driven emergencies. The studies center on conditions such as acute ischemic stroke, high-risk transient ischemic attack, atherosclerotic cardiovascular disease, and forms of heart failure complicated by kidney impairment, with an emphasis on testing new therapies and improving patient outcomes.
- Research on acute ischemic stroke is evaluating treatments aimed at reducing the risk of recurrent stroke and improving recovery after a major cerebrovascular event.
- Trials in heart failure and kidney disease are studying whether new treatment combinations can better lower cardiovascular death and heart failure events.
- Studies in worsening heart failure are exploring whether novel therapies can improve symptoms, fluid balance, and quality-of-life measures.
- Work on atherosclerotic cardiovascular disease is assessing whether investigational treatments can reduce serious heart, stroke, and vascular complications.
- Stroke-focused research is also examining whether treatment can improve functional recovery in people who present beyond the usual treatment window.
The site’s small but focused program, supported by two investigators, highlights practical research aimed at better prevention, treatment, and recovery in major cardiovascular and stroke conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Clinic Judetean de Urgenta Arad
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.